Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years
- 12 July 2017
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 14 (1), 62-70
- https://doi.org/10.1016/j.jalz.2017.06.2264
Abstract
Introduction The best‐established cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease are levels of amyloid β 42 (Aβ42), total tau (tau), and phosphorylated tau 181 (ptau). We examined whether a widely used commercial immunoassay for CSF Aβ42, tau, and ptau provided stable measurements for more than 10 years. Methods INNOTEST assay values for CSF Aβ42, tau, and ptau from Washington University in St. Louis and VU Medical Center, Amsterdam, were evaluated. Results Aβ42 values as measured by the INNOTEST assay drifted upward by approximately 3% per year over the past decade. Tau values remained relatively stable, whereas results for ptau were mixed. Discussion Assay drift may reduce statistical power or even confound analyses. The drift in INNOTEST Aβ42 values may reduce diagnostic accuracy for Alzheimer's disease in the clinic. We recommend methods to account for assay drift in existing data sets and to reduce assay drift in future studies.Funding Information
- National Institute on Aging (P01AG026276, P01AG03991)
- European Commission
- Internationale Stichting Alzheimer Onderzoek
- Alzheimer's Drug Discovery Foundation
- National Institutes of Health (P50AG005681, P01AG003991, P01AG026276, UF01AG032438)
- National Institutes of Health (P50AG005681, P01AG003991, P01AG026276)
- GE Healthcare
- Danone Research Centre for Specialised Nutrition
- National Institutes of Health (P50AG005681, P01AG003991, P01AG026276, R01AG034119, R01AG053550)
- National Institutes of Health (P50AG005681, P01AG003991, P01AG026276, UF01AG03243807)
This publication has 28 references indexed in Scilit:
- Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s DiseaseScience Translational Medicine, 2014
- Alzheimer disease in the United States (2010–2050) estimated using the 2010 censusNeurology, 2013
- Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years laterNeurology, 2013
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseThe New England Journal of Medicine, 2012
- Neuropathologic Substrate of Mild Cognitive ImpairmentArchives of Neurology, 2006
- Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer DiseaseArchives of Neurology, 2001
- Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's DiseaseJournal of Molecular Neuroscience, 2001
- Neuropathological and Neuropsychological Changes in “Normal” AgingJournal of Neuropathology and Experimental Neurology, 1998
- Frequency of Stages of Alzheimer-Related Lesions in Different Age CategoriesNeurobiology of Aging, 1997
- Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s DiseaseJournal of Neuroscience, 1996